Cargando…

Tacrolimus pharmacokinetics are influenced by CYP3A5, age, and concomitant fluconazole in pediatric kidney transplant patients

Tacrolimus, the most common immunosuppressant for organ transplant, has a narrow therapeutic range and is metabolized by CYP3A4/5. Trough concentration monitoring and dosing adjustments are used to reach a therapeutic range. CYP3A5 intermediate and normal metabolizers (*1 allele carriers; IM/NM) dem...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alghamdi, Alaa, Seay, Sarah, Hooper, David K., Varnell, Charles D., Darland, Leanna, Mizuno, Tomoyuki, Lazear, Danielle, Ramsey, Laura B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582663/ https://www.ncbi.nlm.nih.gov/pubmed/37340713 http://dx.doi.org/10.1111/cts.13571

Ejemplares similares

Frequency of CYP3A5 Genetic Polymorphisms and Tacrolimus Pharmacokinetics in Pediatric Liver Transplantation
por: Buendía, Jefferson Antonio, et al.
Publicado: (2020)

Effects of the CYP3A inhibitors, voriconazole, itraconazole, and fluconazole on the pharmacokinetics of osimertinib in rats
por: Lou, Yutao, et al.
Publicado: (2023)

Synergistic effects of tacrolimus and azole antifungal compounds in fluconazole-susceptible and fluconazole-resistant Candida glabrata isolates
por: Denardi, Laura Bedin, et al.
Publicado: (2015)

Tacrolimus Increases the Effectiveness of Itraconazole and Fluconazole against Sporothrix spp.
por: Borba-Santos, Luana P., et al.
Publicado: (2017)

Antifungal activities of tacrolimus in combination with antifungal agents against fluconazole-susceptible and fluconazole-resistant Trichosporon asahii isolates
por: Kubiça, Thaís Felli, et al.
Publicado: (2016)

Early impact of donor CYP3A5 genotype and Graft-to-Recipient Weight Ratio on tacrolimus pharmacokinetics in pediatric liver transplant patients
por: Pinon, Michele, et al.
Publicado: (2021)

Effect of Fluconazole Coadministration and CYP2C9 Genetic Polymorphism on Siponimod Pharmacokinetics in Healthy Subjects
por: Gardin, Anne, et al.
Publicado: (2018)

The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients
por: Lunde, Ingrid, et al.
Publicado: (2014)

CYP3A5 and ABCB1 genotype influence tacrolimus and sirolimus pharmacokinetics in renal transplant recipients
por: Li, Yi, et al.
Publicado: (2015)

Effect of CYP3A4*22, CYP3A5*3, and CYP3A Combined Genotypes on Cyclosporine, Everolimus, and Tacrolimus Pharmacokinetics in Renal Transplantation
por: Moes, D J A R, et al.
Publicado: (2014)

Tacrolimus Pharmacokinetic and Pharmacogenomic Differences between Adults and Pediatric Solid Organ Transplant Recipients
por: Marfo, Kwaku, et al.
Publicado: (2010)

Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of Tacrolimus in Kidney Transplantation
por: Yu, Meng, et al.
Publicado: (2018)

In vitro studies and in silico predictions of fluconazole and CYP2C9 genetic polymorphism impact on siponimod metabolism and pharmacokinetics
por: Jin, Yi, et al.
Publicado: (2017)

Impact of concomitant fluconazole on direct oral anticoagulant bleeding risk
por: Cid, Allison, et al.
Publicado: (2022)

The Impact of CYP3A4*22 on Tacrolimus Pharmacokinetics and Outcome in Clinical Practice at a Single Kidney Transplant Center
por: Abdel-Kahaar, Emaad, et al.
Publicado: (2019)

Physiologically-Based Pharmacokinetic Modeling Characterizes the CYP3A-Mediated Drug-Drug Interaction Between Fluconazole and Sildenafil in Infants
por: Salerno, Sara N., et al.
Publicado: (2020)

Population Pharmacokinetics and Initial Dosage Optimization of Tacrolimus in Pediatric Hematopoietic Stem Cell Transplant Patients
por: Liu, Xiao-Lin, et al.
Publicado: (2022)

Population pharmacokinetics of everolimus in adult liver transplant patients: Comparison to tacrolimus disposition and extrapolation to pediatrics
por: Itohara, Kotaro, et al.
Publicado: (2022)

Immunomodulation in stable renal transplant recipients with concomitant tacrolimus and sirolimus therapy
por: Khanna, Ashwani, et al.
Publicado: (2002)

Clinical Pharmacokinetics of Tacrolimus in Iranian Liver Transplant Recipients
por: Nasiri-Toosi, Zahra, et al.
Publicado: (2014)

A Randomized Pharmacokinetic Study of Generic Tacrolimus Versus Reference Tacrolimus in Kidney Transplant Recipients
por: Alloway, R R, et al.
Publicado: (2012)

A Population Pharmacokinetic Model to Predict the Individual Starting Dose of Tacrolimus Following Pediatric Renal Transplantation
por: Andrews, Louise M., et al.
Publicado: (2017)

Population Pharmacokinetic Model Development of Tacrolimus in Pediatric and Young Adult Patients Undergoing Hematopoietic Cell Transplantation
por: Brooks, Jordan T., et al.
Publicado: (2021)

Drug-induced CYP induction as therapy for tacrolimus intoxication
por: Hoppe, John M., et al.
Publicado: (2022)

The learning health system for pediatric nephrology: building better systems to improve health
por: Varnell, Charles D., et al.
Publicado: (2022)

Effects of the CYP3A4*1B Genetic Polymorphism on the Pharmacokinetics of Tacrolimus in Adult Renal Transplant Recipients: A Meta-Analysis
por: Shi, Wei-Long, et al.
Publicado: (2015)

Physiologically based pharmacokinetic modeling of tacrolimus for food–drug and CYP3A drug–drug–gene interaction predictions
por: Loer, Helena Leonie Hanae, et al.
Publicado: (2023)

The Barriers Assessment Tool—A Patient-Centered Measure of Adherence Barriers in Pediatric Kidney Transplantation
por: Varnell, Charles D., et al.
Publicado: (2023)

Pharmacokinetics of tacrolimus according to body composition in recipients of kidney transplants
por: Han, Seung Seok, et al.
Publicado: (2012)

Pharmacokinetics of apixaban and tacrolimus or cyclosporine in kidney and lung transplant recipients
por: Mansell, Holly, et al.
Publicado: (2022)

Body composition is associated with tacrolimus pharmacokinetics in kidney transplant recipients
por: Francke, M. I., et al.
Publicado: (2022)

Insights into the Pharmacogenetics of Tacrolimus Pharmacokinetics and Pharmacodynamics
por: Brunet, Mercè, et al.
Publicado: (2022)

Evidence of CYP3A Allosterism In Vivo: Analysis of Fluconazole and Midazolam Interaction
por: Yang, Jing, et al.
Publicado: (2011)

Population pharmacokinetics of tacrolimus in pediatric refractory nephrotic syndrome and a summary of other pediatric disease models
por: Wang, Dongdong, et al.
Publicado: (2019)

Pharmacokinetic Variability and Target Attainment of Fluconazole in Critically Ill Patients
por: Van Daele, Ruth, et al.
Publicado: (2021)

CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment
por: Chen, Lucy, et al.
Publicado: (2018)

Fanconi Syndrome Induced by Concomitant HIV PrEP and Tacrolimus
por: Linn, Becky S., et al.
Publicado: (2021)

GRWR Correlates with the Metabolism of Tacrolimus after Pediatric Living Donor Liver Transplantation According to Donor CYP3A5 Polymorphism
por: Wan, Ping, et al.
Publicado: (2022)

The Population Pharmacokinetic Models of Tacrolimus in Chinese Adult Liver Transplantation Patients
por: Zhu, Liqin, et al.
Publicado: (2014)

Race and sex associations with tacrolimus pharmacokinetics in stable kidney transplant recipients
por: Tornatore, Kathleen M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9mi96hpia4r3bd647gm3pda63f